Hematologics
Private Company
Funding information not available
Overview
Hematologics is a private, revenue-generating diagnostics company that has established itself as a recognized leader in MRD testing for hematologic cancers. Its core technology is the proprietary ∆N:™ (Difference from Normal) flow cytometry platform, which it integrates with a full suite of services including next-generation sequencing, cytogenetics, and cell sorting. The company serves both clinical and biopharmaceutical clients, providing critical data for patient management and clinical trial support. With a deep scientific team and a continuous focus on assay standardization and integration, Hematologics is positioned at the forefront of precision diagnostics in hematology.
Technology Platform
Proprietary ∆N:™ (Difference from Normal) flow cytometry integrated with clinical cell sorting (FACS), next-generation sequencing (NGS), cytogenetics, FISH on sorted cells (FACS-FISH), and SNP/microarray analysis for a comprehensive genotype-phenotype diagnostic platform.
Opportunities
Risk Factors
Competitive Landscape
Hematologics competes with large national reference labs (e.g., LabCorp, Quest) offering broad menus, and specialized oncology labs with MRD focus. Its key differentiator is the proprietary ∆N:™ flow cytometry approach and its deep integration of cell sorting with molecular techniques, offering unique insights for complex cases that generic services cannot match.